Friday, October-28-16 News in Brief Restricted Reimbursement for DAAs Hinders Progress Towards Global Hepatitis C Eradication Goal October 27, 2016 There are significant differences in the criteria for reimbursing for direct-acting antivirals (DAAs) for patients with hepatitis C virus (HCV) among the provinces in Canada, according to the results of a recent study. Conducted by Alison Marshall, MA, of The Kirby Institute, and colleagues, the study...